Singapore, Jan. 31 -- based health deep tech startup transforming chronic disease management through predictive analytics, has raised $3.5 million in Series A financing led by East Ventures, a pioneering and leading sector-agnostic venture capital firm focusing on Southeast Asia. This round of investment also saw participation of Elev8, Seed Capitals, and other existing shareholders.

The funding will allow Mesh Bio to offer its digital twin technologies to healthcare providers and scale the deployment of these solutions across Hong Kong and Southeast Asia, mainly Indonesia and the Philippines.

This new investment comes three months after Mesh Bio secured historic regulatory approval and an implementation pilot with public health systems...